Cytokine Release Syndrome Induced by Combination Therapy With Nivolumab and Ipilimumab in Lower Palpebral Conjunctival Melanoma: A Case Report
The Journal of Dermatology · 2026-10 · 53 (10) · 1537-1541
DOI: 10.1111/1346-8138.70413 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Dermatology, online erschienen am 23.07.2026. Verfasst von Kaito Suzuki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermato-Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Melanoma, Nivolumab, Ipilimumab, Cytokine Release Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Cytokine release syndrome (CRS) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening immune‐related adverse event (irAE). CRS has been recognized as a complication of chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific T‐cell engager (BiTE) therapy, but remains exceedingly rare as a complication of ICI therapy. Here, we report a case of CRS that developed after combination therapy with nivolumab and ipilimumab in a woman in her 60s with advanced conjunctival melanoma. The diagnosis was based on the clinical course and imaging findings together with characteristic laboratory abnormalities, including systemic inflammation, hepatic dysfunction, coagulopathy, and marked hyperferritinemia. This case highlights the importance of careful exclusion of infectious and neoplastic diseases for early diagnosis, demonstrates that ICI‐related CRS can relapse after initial control, and shows that it may overlap with hemophagocytic lymphohistiocytosis (HLH)–like syndromes. Given the central role of interleukin‐6 (IL‐6) in CRS, early administration of tocilizumab may contribute to rapid control of inflammation and reduction of steroid exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermato-Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Onco-Rheumatology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Diagnostic Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Kaito Suzuki, Koichi Takeda, Shoichiro Ishizuki, Ryugo Sekiyama
Zitieren
APA
Suzuki, K., Uehara, J., Takeda, K., Ishizuki, S., Aoki, S., Sekiyama, R., Akiya, M., & Yoshino, K. (2026). Cytokine Release Syndrome Induced by Combination Therapy With Nivolumab and Ipilimumab in Lower Palpebral Conjunctival Melanoma: A Case Report. The Journal of Dermatology, 53(10), 1537-1541. https://doi.org/10.1111/1346-8138.70413
Vancouver
Suzuki K, Uehara J, Takeda K, Ishizuki S, Aoki S, Sekiyama R, et al. Cytokine Release Syndrome Induced by Combination Therapy With Nivolumab and Ipilimumab in Lower Palpebral Conjunctival Melanoma: A Case Report. The Journal of Dermatology. 2026;53(10):1537-1541. doi:10.1111/1346-8138.70413
BibTeX
@article{Suzuki2026,
author = {Suzuki, Kaito and Uehara, Jiro and Takeda, Koichi and Ishizuki, Shoichiro and Aoki, Sayumi and Sekiyama, Ryugo and Akiya, Masafumi and Yoshino, Koji},
title = {Cytokine Release Syndrome Induced by Combination Therapy With Nivolumab and Ipilimumab in Lower Palpebral Conjunctival Melanoma: A Case Report},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {10},
pages = {1537--1541},
doi = {10.1111/1346-8138.70413}
}
EUVIMED